 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...7677787980818283848586...235236» |
- || 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Review, Journal: Leukocytoclastic vasculitis presenting clinically as bullous pyoderma gangrenosum following leucovorin, fluorouracil and oxaliplatin chemotherapy: a rare case report and literature review. (Pubmed Central) - Sep 29, 2022
The FOLFOX chemotherapy regimen is increasingly administered considering the rising incidence of gastrointestinal cancers. Hence, our understanding of its possible side effects and complications must be heightened.
- | Vectibix (panitumumab) / Amgen, Takeda
Journal: Colorectal signet-ring cell carcinoma treated with FOLFOX plus panitumumab. (Pubmed Central) - Sep 29, 2022
Hence, our understanding of its possible side effects and complications must be heightened. No abstract available
- | Enrollment open: Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer (clinicaltrials.gov) - Sep 29, 2022
P2, N=38, Recruiting, Sponsor: Rutgers, The State University of New Jersey
No abstract available Not yet recruiting --> Recruiting
- | Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly
Trial completion, Combination therapy, Metastases: Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial. (clinicaltrials.gov) - Sep 29, 2022
P2, N=43, Completed, Sponsor: AIO-Studien-gGmbH
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | leucovorin calcium / Generic mfg.
Trial suspension: Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium (clinicaltrials.gov) - Sep 28, 2022
P2, N=80, Suspended, Sponsor: Rossignol Medical Center
Active, not recruiting --> Completed Recruiting --> Suspended
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion date, Trial primary completion date: Peri-operative SLOG for Localized Pancreatic Cancer (clinicaltrials.gov) - Sep 28, 2022
P2, N=40, Recruiting, Sponsor: National Health Research Institutes, Taiwan
Recruiting --> Suspended Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2022 --> Aug 2023
- | leucovorin calcium / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism (clinicaltrials.gov) - Sep 28, 2022
P2, N=80, Active, not recruiting, Sponsor: Rossignol Medical Center
Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2022 --> Aug 2023 Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- ||||||| Graspa (eryaspase) / PHAXIAM Therap
Trial completion, Trial completion date, Combination therapy: Trybeca-1: Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC (clinicaltrials.gov) - Sep 28, 2022
P3, N=512, Completed, Sponsor: ERYtech Pharma
Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 Active, not recruiting --> Completed | Trial completion date: Oct 2021 --> Jan 2022
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical: Great question! 🤔I would try to cover all bases with adjuvant FOLFOX plus anti PD1 if covered- in case adjuvant immunotherapy works as well as adjuvant irinotecan and adjuvant anti EGFR. (Twitter) - Sep 27, 2022
- | Trial completion date, Trial primary completion date, Metastases: Redefining FOLFIORINOX in Older Pancreatic Cancer Patients (clinicaltrials.gov) - Sep 27, 2022
P2, N=37, Recruiting, Sponsor: Fox Chase Cancer Center
Active, not recruiting --> Completed | Trial completion date: Oct 2021 --> Jan 2022 Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2022 --> Sep 2023
- || aplitabart (IGM-8444) / IGM Biosciences
Trial completion date, Trial primary completion date: IGM-8444-001: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers (clinicaltrials.gov) - Sep 27, 2022
P1, N=350, Recruiting, Sponsor: IGM Biosciences, Inc.
Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2022 --> Sep 2023 Trial completion date: Oct 2023 --> Oct 2025 | Trial primary completion date: Aug 2023 --> Aug 2025
- | Enrollment closed, Trial primary completion date, Metastases: Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Sep 27, 2022
P=N/A, N=251, Active, not recruiting, Sponsor: Oslo University Hospital
Trial completion date: Oct 2023 --> Oct 2025 | Trial primary completion date: Aug 2023 --> Aug 2025 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2023 --> Oct 2022
- |||| oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: D6070C00005: MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. (clinicaltrials.gov) - Sep 27, 2022
P1b/2, N=212, Completed, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2023 --> Oct 2022 Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Jul 2022 | Trial primary completion date: Dec 2022 --> Jul 2022
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical: It’s a challenging disease but lots of patients not gonna be candidates for FOLFIRINOX so we need options (Twitter) - Sep 26, 2022
- | Trial initiation date, MRI, Metastases: SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer (clinicaltrials.gov) - Sep 26, 2022
P1, N=25, Not yet recruiting, Sponsor: University of Miami
Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Jul 2022 | Trial primary completion date: Dec 2022 --> Jul 2022 Initiation date: Jun 2022 --> Oct 2022
- ||||| oxaliplatin / Generic mfg., gemcitabine / Generic mfg.
Trial initiation date: Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature (clinicaltrials.gov) - Sep 26, 2022
P3, N=394, Not yet recruiting, Sponsor: John Neoptolemos
Initiation date: Jun 2022 --> Oct 2022 Initiation date: Jul 2022 --> Nov 2022
- ||| Lumakras (sotorasib) / Amgen
Enrollment open, Metastases: Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer (clinicaltrials.gov) - Sep 26, 2022
P1/2, N=59, Recruiting, Sponsor: Devalingam Mahalingam
Initiation date: Jul 2022 --> Nov 2022 Not yet recruiting --> Recruiting
- | Enrollment closed, Trial primary completion date: Mature B-Cell Lymphoma And Leukemia Study III (clinicaltrials.gov) - Sep 26, 2022
P2/3, N=128, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2023 --> Aug 2023
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS
Clinical: Question for Oncology twitter: A patient with PSM2 deficient, metastatic gastric adeno, HER2 -. Has complete metabolic response after 8 cycles of FOLFOX + Nivolumab. Would you still continue FOLFOX? Or treat with Nivolumab alone?@YJanjigianMD @Thalcin (Twitter) - Sep 25, 2022
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Retrospective data, Journal: Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma: A multicenter retrospective analysis. (Pubmed Central) - Sep 25, 2022
This study suggests that combination therapy may be more effective than monotherapy. GnP and FFX showed similar and clinically meaningful efficacy for patients with metastatic or recurrent PASC.
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS
Thank you for your insight. Juxtaposing the 2 trials, CM649 ✅exclusively focuses on adenocarcinoma, ✅has good data on signet ring cell carcinoma ✅apparently more favorable toxicity profile ✅higher ORR ➡️My opinion:FOLFOX+NIVO Q4W in 1L HER2 neg met GEJC-Adenocarcinoma (Twitter) - Sep 25, 2022
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: I’d argue that there’s NO data supporting one PD1⛔️over another, or PD1⛔️🆚PDL1⛔️. Not here or any other cancer. If >1 commercial drug is approved, one should alternate choice between pts. Why favor one drug company? 💡For pairing with FOLFOX Q2W can use: ✔️NIVOQ4W or ✔️PEMQ6W (Twitter) - Sep 25, 2022
- || Retrospective data, Review, Journal: Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. (Pubmed Central) - Sep 25, 2022
Neoadjuvant chemotherapy with gemcitabine or S-1 and FOLFIRINOX improved the survival outcomes...NAT improved the OS, R0 resection rate, and node-negativity rate compared with UFS. Standardizing treatment regimens based on high-quality evidence is fundamental for developing an optimal protocol.
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
P2 data, Journal: Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial. (Pubmed Central) - Sep 25, 2022
In the bevacizumab arm, a significant difference in RFS existed between the low and high TRG groups, while in the cetuximab arm, for TRG, mTRG, and DH, the low and absent/rare groups demonstrated significantly longer RFS than the high and focal/diffuse groups, respectively. TRG could estimate RFS in patients who underwent liver metastasectomy after bevacizumab or cetuximab chemotherapy.
- | Biomarker, Journal, Circulating tumor DNA, Epigenetic controller: NPY Gene Methylation in Circulating Tumor DNA as an Early Biomarker for Treatment Effect in Metastatic Colorectal Cancer. (Pubmed Central) - Sep 25, 2022
The aim of the present study was to investigate hypermethylated neuropeptide Y circulating tumor DNA (meth-NPY) as an early biomarker for treatment effect and monitoring in 70 mCRC patients receiving first-line treatment in the FOLFOXIRI-Toco trial...In conclusion, early meth-NPY response proved superior to response according to RECIST 1.1 with respect to predicting improved PFS. Meth-NPY is an early indicator of progression, allowing treatment reorientation at an earlier timepoint.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Primary Clear Cell Carcinoma of the Pancreas: A Rare Case Report. (Pubmed Central) - Sep 24, 2022
The patient is still alive after his third radiofrequency ablation for the newly-developed hepatic mass. Immunohistochemical staining for MUC-1 and HNF-1β, as well as histologic feature is very helpful for the diagnosis of primary pancreatic clear cell carcinoma with imaging methods for metastasis exclusion.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS
I would go w/ FOLFOX plus Nivo. (Twitter) - Sep 24, 2022
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS
Dear @RenoHemonc Same here I would favor FOLFOX + Nivolumab Good data also on signet ring cell carcinoma (Twitter) - Sep 24, 2022
- ||| Clinical: Both are ok esp given high PDL1 . KN 590 majority pts were SCC. In adeno, lot of folks prefer Nivo FOLFOX q 2 weeks -If CAPOX PLANNED q 3 weeks Pembro fits in nicely . -If Pembro is planned with FOLFOX, use q 6 weeks to correspond with FOLFOX. (Twitter) - Sep 24, 2022
- | Tasigna (nilotinib) / Novartis, Inhibikase
Journal: Comprehensive molecular docking and dynamic simulations for drug repurposing of clinical drugs against multiple cancer kinase targets. (Pubmed Central) - Sep 24, 2022
To further validate the final docking results at atomistic level, molecular dynamics simulations were performed to ascertain the stability of the protein-ligand complex. The study enables repurposing of drugs and lead identification by employing a host of structure and ligand based virtual screening tools and techniques.Communicated by Ramaswamy H. Sarma.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Retrospective data, Journal: Severe oral mucositis relating to pain and worse oral condition among patients with solid tumors undergoing treatment with FOLFIRI and 5-FU: a retrospective study. (Pubmed Central) - Sep 24, 2022
Individuals with tumors who presented severe OM had greater severity of oral pain and worse oral health. Use of the FOLFIRI protocol was associated with higher prevalence of severe OM, while use of 5-fluorouracil (5-FU) was correlated with worse oral condition.
- | leucovorin calcium / Generic mfg.
Preclinical, Journal: Histologic Evaluation of the Effects of Folinic Acid Chitosan Hydrogel and Botulinum Toxin A on Wound Repair of Cleft Lip Surgery in Rats. (Pubmed Central) - Sep 24, 2022
While injection of botulinum toxin A provides less fibroblast proliferation and collagen deposition, and thus lower potential for scar formation compared with the folinic acid group. Therefore, in wounds of the esthetic zone, such as cleft lip defects, the application of botulinum toxin A shows promising results.
- | Journal, IO biomarker: Pancreatic Adenocarcinoma Management. (Pubmed Central) - Sep 24, 2022
The addition of nab-paclitaxel to the traditional gemcitabine regimen added another option for treatment...In this review article, we discuss the key extant literature relevant to various stages of pancreatic cancer. We also summarize ongoing clinical trials which may guide future treatments.
- | oxaliplatin / Generic mfg.
Journal: Clinically Relevant Model of Oxaliplatin-Induced Sinusoidal Obstruction Syndrome. (Pubmed Central) - Sep 24, 2022
We also summarize ongoing clinical trials which may guide future treatments. With distinct differences between monocrotaline-induced rat SOS and human/pig OXCx-SOS, our pig OXCx-SOS model serves as a preclinical platform for future investigations to dissect the pathophysiology of OXCx-SOS and seek preventive strategies.
- | 5-fluorouracil / Generic mfg.
Journal, Real-world evidence: Hepatic Arterial Infusion Chemotherapy as a Timing Strategy for Conversion Surgery to Treat Hepatocellular Carcinoma: A Single-Center Real-World Study. (Pubmed Central) - Sep 23, 2022
The prognosis of advanced HCC after conversion surgery is comparable to that after direct surgery. Rather than increasing pCR, more HAIC cycles can exacerbate liver dysfunction and surgery-related complications.
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Clinical, Journal: Management of elderly patients with unresectable pancreatic cancer. (Pubmed Central) - Sep 23, 2022
It is expected that geriatric assessment will elucidate the eligibility criteria for those regimens in elderly individuals. Randomized clinical trials are ongoing to establish a standard treatment in the vulnerable elderly with advanced pancreatic cancer, who cannot tolerate the same regimen as in the non-elderly patients.
- | 5-fluorouracil / Generic mfg.
Journal: Neoadjuvant chemotherapy is associated with altered immune cell infiltration and an anti-tumorigenic microenvironment in resected pancreatic cancer. (Pubmed Central) - Sep 23, 2022
Randomized clinical trials are ongoing to establish a standard treatment in the vulnerable elderly with advanced pancreatic cancer, who cannot tolerate the same regimen as in the non-elderly patients. Neoadjuvant chemotherapy with FOLFIRINOX shifts the PDAC immune microenvironment towards an anti-tumorigenic state associated with improved patient survival.
- || We're talking *modified* FOLFOXIRI right? I mean, we are Americans and can't hold our fluoropyrimidines so well... 😆 (Twitter) - Sep 23, 2022
- | Vectibix (panitumumab) / Amgen, Takeda
Journal: Metastasis or sarcoidosis - a diagnostic pitfall in metastatic rectal carcinoma (Pubmed Central) - Sep 23, 2022
The simultaneous appearance of metastatic tumors and sarcoidosis creates a diagnostic dilemma since both manifestations can barely be distinguished in regular imaging technologies. This case report demonstrates that the histological work-up of affected organs with consecutive resections can cure a patient of a metastatic tumor disease, even in the context of simultaneous sarcoidosis.
- |||| For colorectal cancer, FOLFOXIRI/panitumumab did not improve response rate or survival and was more toxic than FOLFOX/panitumumab. https://t.co/U9kn89s792 #colorectalcancer #OncTwitter @ILSONDavid (Twitter) - Sep 22, 2022
- |||| Clinical: 1L BREAKWATER Enrolling now🔥 Phase III trial with patients randomized to E+C alone or E+C+FOLFOX or control (FOLFOX/FOLFOXIRI/CAPOX+Bev) More intro about the trial from Dr @skopetz https://t.co/UuHivtd3Q5 📌To enroll, patients should not have started any tx #CRCTrialsChat (Twitter) - Sep 22, 2022
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
BREAKWATER SLI results #ESMO22 1L E+C+FOLFOX or FOLFIRI comparable 2L E+C+FOLFIRI better? E+C+FOLFIRI–some effect of irinotecan on drug metabolism More SAEs in E+C+ FOLFIRI #CRCTrialsChat (Twitter) - Sep 22, 2022
- ||||| Clinical: 1L BREAKWATER SLI #BRAF mCRC pts on chemo or🎯 tx (E-Encorafenib BRAFi+C Cetux EGFRi) progress due to emergence of resistant clones. 👆 trial 👀at 📌 Activity of 1L E+C 📌 Synergy of E+C+chemo 📌Is it safe? Tolerable? 📌Is E+C+FOLFOX or E+C+FOLFIRI better? #CRCTrialsChat (Twitter) - Sep 22, 2022
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS
FOLFOX plus/ minus Nivo based on Checkmate. Will need to know CPS score. (Twitter) - Sep 22, 2022
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: Technically not wrong to continue FLOT but would favor FOLFOX unless CPS high. No radiation now but consider pre op RT in selected high risk patients who poorly respond to neoadj FLOT (Twitter) - Sep 22, 2022
- acetazolamide / Generic mfg., leucovorin calcium / Generic mfg.
Safety of Ambulatory High-Dose Methotrexate Administration Among Hematological Malignancies Patients in Tertiary Care Center () - Sep 22, 2022 - Abstract #SOHO2022SOHO_703;
Our preliminary results suggest that ambulatory HDMTX is safe, cost effective, and more comfortable for patients. These results encourage the use of this approach more frequently as it decreases hospitalization and thus reduces cost, increases patient satisfaction, and helps to solve the issue of bed crisis.
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Next-generation sequencing: Thanks for ur thoughts, Sam. NGS pending 🤞. Our feeling is that hitting the 🦀 w/ same FLOT 🔨 isn’t going to add anything. We are favoring changing to adjuvant FOLFOX or ECX with the addition of anti PDL1/PD1 after restaging imaging in 4 wks. #datafreezone but need a change. (Twitter) - Sep 21, 2022
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: Do you know the PD-L1 CPS? Textbook answer is to complete FLOT. Have completed adjuvant with FOLFOX+PD-1 ➡️ PD-1 in a few similar cases with high PD-L1. High risk case for sure. (Twitter) - Sep 21, 2022
- | Journal: WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAF Mutant Metastatic Colorectal Cancer: A Multi-Institutional Registry-Based Study (BRACELET Study). (Pubmed Central) - Sep 21, 2022
These results encourage the use of this approach more frequently as it decreases hospitalization and thus reduces cost, increases patient satisfaction, and helps to solve the issue of bed crisis. Triplet therapy had no survival benefit versus doublet therapy in the overall and IPTW cohorts or specific subgroups for real-world patients with BRAF mutant mCRC.